Table 1.
Cohort characteristics
| LB group | HC group | W-value/ χ²-value, p-value | |
|---|---|---|---|
| N | 33 | 36 | |
| Age, years | 76.0 (7) | 66.5 (7) | W = 1006, p < 0.001 |
| Sex, women N (%) | 16 (48.5%) | 21 (58.3%) | χ² (1, 69) = 0.334, p = 0.563 |
| Education, years | 11 (4) | 16 (7.25) | W = 268, p < 0.001 |
| Global cognition (MMSE, total score) | 26.03 (4.5) | 29.05 (1.8) | W = 135, p < 0.001 |
| Attention (WAIS-III Digit span, total score) | 12.21 (3.8) | 13.75 (1.9) | W = 378, p = 0.03 |
| Episodic memory (FCSRT free and cued recall, total score) | 26.08 (22.5) | 45.21 (4.7) | W = 121, p < .001 |
| CSF Aβ 42/40 ratio | 0.073 (0.03) | 0.101 (0.03) | W = 307, p = 0.04 |
| Positive Aβ 42/40 ratio, N (%) | 19 (59%) | 5 (18%) | χ²(1, 57) = 13.491, p = 0.001 |
| CSF p-Tau 181, pg/mL | 53.0 (57.5) | 43.8 (19.9) | W = 551, p = 0.128 |
| Positive p-tau 181 biomarker, N (%) | 16 (48%) | 5 (18%) | χ²(1, 57) = 11.398, p = 0.003 |
Median and IQR are reported in the table if not specified (otherwise count and %). Sex differences were evaluated with the chi2 test, and all other comparisons were performed with Wilcoxon rank sum tests. The difference in positive AD biomarkers was tested with a logistic binary regression including age as a covariate. CSF AD biomarkers were adjusted for age. Measures of cognitive performance were adjusted for education and age. The adjustments were performed by regressing out the effect of the confounder before analysis. 60 participants had undergone CSF testing (32 LB and 28 HC). Cut off for CSF biomarkers were based on the unadjusted values. Cut-offs used were previously validated, including 0.062 for Aβ 42/40 ratio and 63 pg/mL for p-tau52.
Aβ amyloid beta, AD Alzheimer’s disease, CSF Cerebrospinal fluid, FCSRT Free and Cued Selective Reminding Test, HC Healthy controls, LB Lewy body, MMSE Mini Mental State Examination, P-Tau phosphorylated-Tau, WAIS Wechsler Adult Intelligence Scale, WMSA White matter signal abnormalities.